Rheumatoid arthritis (RA) is a heterogeneous syndrome of which a subset of patients develops vascular inflammation. The genetic determinants that confer risk for rheumatoid vasculitis are not known, but patients with vascular complications are known to have an expansion of CD4+CD28null T cells, a cell population potentially involved in endothelial damage. CD4+CD28null T cell clones isolated from RA patients with vasculitis were found to express killer cell immunoglobulin–like receptors (KIRs) with the stimulatory KIR2DS2 often present in the absence of opposing inhibitory receptors with related specificities. To test the hypothesis that the KIR2DS2 gene is involved in the development of vasculitis, association studies were performed. The KIR2DS2 gene was significantly enriched among patients with rheumatoid vasculitis compared with normal individuals (odds ratio 5.56, P = 0.001) and patients with RA but no vasculitis (odds ratio 7.96, P = 0.001). Also, the distribution of human histocompatibility leukocyte antigen (HLA)-C, the putative ligand for KIRs, was significantly different in patients with rheumatoid vasculitis in comparison with the control populations. These data suggest that HLA class I–recognizing receptors and HLA class I genes are genetic risk determinants that modulate the pattern of RA expression. Specifically, KIR2DS2 in conjunction with the appropriate HLA-C ligand may have a role in vascular damage by regulating CD4+CD28null T cells.
Skip Nav Destination
Article navigation
21 May 2001
Article Contents
Article|
May 14 2001
Major Histocompatibility Complex Class I–Recognizing Receptors Are Disease Risk Genes in Rheumatoid Arthritis
Jeng-Hsien Yen,
Jeng-Hsien Yen
aDepartment of Medicine and the Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905
Search for other works by this author on:
Brenda E. Moore,
Brenda E. Moore
aDepartment of Medicine and the Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905
Search for other works by this author on:
Takako Nakajima,
Takako Nakajima
aDepartment of Medicine and the Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905
Search for other works by this author on:
Dirk Scholl,
Dirk Scholl
aDepartment of Medicine and the Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905
Search for other works by this author on:
Daniel J. Schaid,
Daniel J. Schaid
bDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905
Search for other works by this author on:
Cornelia M. Weyand,
Cornelia M. Weyand
aDepartment of Medicine and the Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905
Search for other works by this author on:
Jörg J. Goronzy
Jörg J. Goronzy
aDepartment of Medicine and the Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905
Search for other works by this author on:
Jeng-Hsien Yen
aDepartment of Medicine and the Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905
Brenda E. Moore
aDepartment of Medicine and the Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905
Takako Nakajima
aDepartment of Medicine and the Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905
Dirk Scholl
aDepartment of Medicine and the Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905
Daniel J. Schaid
bDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905
Cornelia M. Weyand
aDepartment of Medicine and the Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905
Jörg J. Goronzy
aDepartment of Medicine and the Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905
Abbreviations used in this paper: KIR, killer cell Ig–like receptor; RA, rheumatoid arthritis; RT, reverse transcription.
Received:
April 20 2000
Revision Requested:
March 20 2001
Accepted:
March 26 2001
Online ISSN: 1540-9538
Print ISSN: 0022-1007
© 2001 The Rockefeller University Press
2001
The Rockefeller University Press
J Exp Med (2001) 193 (10): 1159–1168.
Article history
Received:
April 20 2000
Revision Requested:
March 20 2001
Accepted:
March 26 2001
Citation
Jeng-Hsien Yen, Brenda E. Moore, Takako Nakajima, Dirk Scholl, Daniel J. Schaid, Cornelia M. Weyand, Jörg J. Goronzy; Major Histocompatibility Complex Class I–Recognizing Receptors Are Disease Risk Genes in Rheumatoid Arthritis. J Exp Med 21 May 2001; 193 (10): 1159–1168. doi: https://doi.org/10.1084/jem.193.10.1159
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement